Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein

Vaccine

Volumn 31, Issue 42, 2013, Pages 4923-4930

  Céspedes, Nora ^a,b,c   Arévalo Herrera, Myriam ^a,c   Felger, Ingrid ^e   Reed, Steve ^f   Kajava, Andrey V ^g   Corradin, Giampietro ^b   Herrera, Sócrates ^a,d  

^a Malaria Vaccine and Drug Development Center (MVDC)   (Colombia)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSIDAD DEL VALLE   (Colombia)

^d Caucaseco Scientific Research Centre   (Colombia)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^f INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^g UNIV MONTPELLIER   (France)

Author keywords

CS protein; Long synthetic peptide; Malaria; Mice; Plasmodium vivax; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CHIMERIC PROTEIN; CIRCUMSPOROZOITE PROTEIN; MONTANIDE ISA 51;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENDEMIC DISEASE; HEPATOMA CELL; HUMAN; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; SPOROZOITE; WESTERN BLOTTING;

CS PROTEIN; LONG SYNTHETIC PEPTIDE; MALARIA; MICE; PLASMODIUM VIVAX; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; BLOTTING, WESTERN; CELL LINE; COLOMBIA; FLUORESCENT ANTIBODY TECHNIQUE; HEPATOCYTES; HUMANS; MALARIA VACCINES; MICE; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC;

EID: 84884209205     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.082     Document Type: Article

References (50)

1. Guerra C.A., Howes R.E., Patil A.P., Gething P.W., Van Boeckel T.P., Temperley W.H., et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLOS Neglected Tropical Diseases 2010, 4:e774.
2. Kochar D.K., Das A., Kochar S.K., Saxena V., Sirohi P., Garg S., et al. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in Northwestern India. American Journal of Tropical Medicine and Hygiene 2009, 80:194-198.
3. Lacerda M.V., Hipolito J.R., Passos L.N. Chronic Plasmodium vivax infection in a patient with splenomegaly and severe thrombocytopenia. Revista da Sociedade Brasileira de Medicina Tropical 2008, 41:522-523.
4. Ruebush T.K., Zegarra J., Cairo J., Andersen E.M., Green M., Pillai D.R., et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. American Journal of Tropical Medicine and Hygiene 2003, 69:548-552.
5. Tjitra E., Anstey N.M., Sugiarto P., Warikar N., Kenangalem E., Karyana M., et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Medicine 2008, 5:e128.
6. Greenwood B.M., Targett G.A. Malaria vaccines and the new malaria agenda. Clinical Microbiology and Infection 2011, 17:1600-1607.
7. Hill A.V. Vaccines against malaria. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 2011, 366:2806-2814.
8. Schwartz L., Brown G.V., Genton B., Moorthy V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malaria Journal 2012, 11:11.
9. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G., Kabwende A.L., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New England Journal of Medicine 2012, 367:2284-2295.
10. Cochrane A.H., Aikawa M., Jeng M., Nussenzweig R.S. Antibody-induced ultrastructural changes of malarial sporozoites. Journal of Immunology 1976, 116:859-867.
11. Lopez J.A., Roggero M.A., Duombo O., Gonzalez J.M., Tolle R., Koita O., et al. Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors. American Journal of Tropical Medicine and Hygiene 1996, 55:424-429.
12. Nardin E.H., Nussenzweig R.S. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annual Review of Immunology 1993, 11:687-727.
13. Arnot D.E., Barnwell J.W., Tam J.P., Nussenzweig V., Nussenzweig R.S., Enea V. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 1985, 230:815-818.
14. Rosenberg R., Wirtz R.A., Lanar D.E., Sattabongkot J., Hall T., Waters A.P., et al. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science 1989, 245:973-976.
15. Cerami C., Frevert U., Sinnis P., Takacs B., Clavijo P., Santos M.J., et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 1992, 70:1021-1033.
16. Frevert U., Sinnis P., Cerami C., Shreffler W., Takacs B., Nussenzweig V. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. Journal of Experimental Medicine 1993, 177:1287-1298.
17. Coppi A., Natarajan R., Pradel G., Bennett B.L., James E.R., Roggero M.A., et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. Journal of Experimental Medicine 2011, 208:341-356.
18. Coppi A., Pinzon-Ortiz C., Hutter C., Sinnis P. The plasmodium circumsporozoite protein is proteolytically processed during cell invasion. Journal of Experimental Medicine 2005, 201:27-33.
19. Arevalo-Herrera M., Roggero M.A., Gonzalez J.M., Vergara J., Corradin G., Lopez J.A., et al. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Annals of Tropical Medicine and Parasitology 1998, 92:539-551.
20. Arevalo-Herrera M., Valencia A.Z., Vergara J., Bonelo A., Fleischhauer K., Gonzalez J.M., et al. Identification of HLA-A2 restricted CD8(+) t-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunology 2002, 24:161-169.
21. Herrera S., Escobar P., de Plata C., Avila G.I., Corradin G., Herrera M.A. Human recognition of T cell epitopes on the Plasmodium vivax circumsporozoite protein. Journal of Immunology 1992, 148:3986-3990.
22. Arevalo-Herrera M., Vera O., Castellanos A., Cespedes N., Soto L., Corradin G., et al. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in Montanide ISA 720 and Montanide ISA 51 adjuvants. American Journal of Tropical Medicine and Hygiene 2011, 84:21-27.
23. Herrera S., Bonelo A., Perlaza B.L., Fernandez O.L., Victoria L., Lenis A.M., et al. Safety and elicitation of humoral and cellular responses in Colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. American Journal of Tropical Medicine and Hygiene 2005, 73:3-9.
24. Herrera S., Bonelo A., Perlaza B.L., Valencia A.Z., Cifuentes C., Hurtado S. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. International Journal for Parasitology 2004, 34:1535-1546.
25. Herrera S., Fernandez O.L., Vera O., Cardenas W., Ramirez O., Palacios R., et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with Montanide ISA 720 or Montanide ISA 51. American Journal of Tropical Medicine and Hygiene 2011, 84:12-20.
26. Lumsden J.M., Nurmukhambetova S., Klein J.H., Sattabongkot J., Bennett J.W., Bertholet S., et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 2012, 30:3311-3319.
27. Yadava A., Sattabongkot J., Washington M.A., Ware L.A., Majam V., Zheng H., et al. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infection and Immunity 2007, 75:1177-1185.
28. Atherton E., Logan J.C., Sheppard R.C. Peptide synthesis. II. Procedures for solid phase synthesis using N-fluorenyl-methysoxycarbamylamino-acid on polymide supports: synthesis of substance P and of acyl carrier protein 65-74 decapeptide. Journal of the Chemical Society, Perkin Transactions 1981, 1:538-548.
29. Verdini A., Terenzi S., Brossard V., Roggero M., Corradin G. Oxidative folding of synthetic polypeptides S-protected as tert-butylthio derivatives. Journal of Peptide Science 2008, 14:1271-1282.
30. Dayringer H.E., Tramontano A., Sprang S.R., Fletterick R.J. Interactive program for visualization and modelling of proteins, nucleic acids and small molecules. Journal of Molecular Graphics 1986, 4:82-87.
31. Alpers M.P., al-Yaman F., Beck H.P., Bhatia K.K., Hii J., Lewis D.J., et al. The malaria vaccine epidemiology and evaluation project of Papua New Guinea: rationale and baseline studies. Papua New Guinea Medical Journal 1992, 35:285-297.
32. Mendez F., Carrasquilla G., Munoz A. Risk factors associated with malaria infection in an urban setting. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000, 94:367-371.
33. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and type 1 cellular immune responses with fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
34. Coler R.N., Baldwin S.L., Shaverdian N., Bertholet S., Reed S.J., Raman V.S., et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 2010, 5:e13677.
35. Hurtado S., Salas M.L., Romero J.F., Zapata J.C., Ortiz H., Arevalo-Herrera M., et al. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Annals of Tropical Medicine and Parasitology 1997, 91:49-60.
36. Villard V., Agak G.W., Frank G., Jafarshad A., Servis C., Nebie I., et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS ONE 2007, 2:e645.
37. Olugbile S., Villard V., Bertholet S., Jafarshad A., Kulangara C., Roussilhon C., et al. Malaria vaccine candidate: design of a multivalent subunit alpha-helical coiled coil poly-epitope. Vaccine 2011, 29:7090-7099.
38. Koepfli C., Ross A., Kiniboro B., Smith T.A., Zimmerman P.A., Siba P., et al. Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLOS Neglected Tropical Diseases 2011, 5:e1424.
39. Arevalo-Herrera M., Quinones M.L., Guerra C., Cespedes N., Giron S., Ahumada M., et al. Malaria in selected non-Amazonian countries of Latin America. Acta Tropica 2012, 121:303-314.
40. Hernandez-Martinez M.A., Escalante A.A., Arevalo-Herrera M., Herrera S. Antigenic diversity of the Plasmodium vivax circumsporozoite protein in parasite isolates of Western Colombia. American Journal of Tropical Medicine and Hygiene 2011, 84:51-57.
41. Gonzalez J.M., Hurtado S., Arevalo-Herrera M., Herrera S. Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates. Memorias do Instituto Oswaldo Cruz 2001, 96:709-712.
42. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nature Reviews Immunology 2009, 9:287-293.
43. McCarthy J.S., Marjason J., Elliott S., Fahey P., Bang G., Malkin E., et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(r) ISA 720. PLoS ONE 2011, 6:e24413.
44. Pierce M.A., Ellis R.D., Martin L.B., Malkin E., Tierney E., Miura K., et al. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 2010, 28:2236-2242.
45. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with Montanide ISA 51. PLoS ONE 2008, 3:e2636.
46. Olugbile S., Kulangara C., Bang G., Bertholet S., Suzarte E., Villard V., et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein Pff0165c. Infection and Immunity 2009, 77:5701-5709.
47. Cochrane A.H., Santoro F., Nussenzweig V., Gwadz R.W., Nussenzweig R.S. Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proceedings of the National Academy of Sciences of the United States of America 1982, 79:5651-5655.
48. Corradin G., Cespedes N., Verdini A., Kajava A.V., Arevalo-Herrera M., Herrera S. Malaria vaccine development using synthetic peptides as a technical platform. Advances in Immunology 2012, 114:107-149.
49. Dosztanyi Z., Csizmok V., Tompa P., Simon I. The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins. Journal of Molecular Biology 2005, 347:827-839.
50. Doud M.B., Koksal A.C., Mi L.Z., Song G., Lu C., Springer T.A. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:7817-7822.